A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates

Sue Grepper, PhD - InSphero

Preparation scheme for the isolation of primary liver cells. Liver cell

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). - Abstract - Europe PMC

Multimodal NASH prognosis using 3D imaging flow cytometry and artificial intelligence to characterize liver cells

Firsocostat treatment leads to decreased lipid accumulation in NASH

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Sue Grepper, PhD - InSphero

Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis - ScienceDirect

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). - Abstract - Europe PMC

Mechanisms of 5-HT receptor antagonists in the regulation of fibrosis in a 3D human liver spheroid model

3D In Vitro MASH Model for Preventive Screening

IJMS, Free Full-Text

IJMS, Free Full-Text

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists